转债代码：118051 转债简称：皓元转债 上海皓元医药股份有限公司2025 年半年度报告 公司代码：688131 公司简称：皓元医药 上海皓元医药股份有限公司 2025 年半年度报告 1 / 285 上海皓元医药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅"第三节管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注，注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人郑保富、主管会计工作负责人李敏及会计机构负责人（会计主管人员）李敏声 明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司根据战略规划、业务发展需要以及 2025 年中期分红安排的相关规定，在保证公司正常资 金需求的前提下，拟向全体股东每 10 股派发现金红利 0.80 元（含 ...

上海皓元医药股份有限公司 章 程 二〇二五年八月 | 第一章 | 总 | 则 | 3 | | --- | --- | --- | --- | | 第二章 | | 经营宗旨和范围 4 | | | 第三章 | 股 | 份 | 4 | | 第一节 | | 股份发行 4 | | | 第二节 | | 股份增减和回购 5 | | | 第三节 | | 股份转让 6 | | | 第四章 | | 股东和股东会 | 7 | | 第一节 | | 股东的一般规定 7 | | | 第二节 | | 控股股东和实际控制人 10 | | | 第三节 | | 股东会的一般规定 11 | | | 第四节 | | 股东会的召集 13 | | | 第五节 | | 股东会的提案与通知 15 | | | 第六节 | | 股东会的召开 16 | | | 第七节 | | 股东会的表决和决议 19 | | | 第五章 | | 董事和董事会 23 | | | 第一节 | | 董事的一般规定 23 | | | 第二节 | | 董事会 27 | | | 第三节 | | 独立董事 30 | | | 第四节 | | 董事会专门委员会 32 | | | 第六章 | | ...

Group 1 - The stock price of Haoyuan Pharmaceutical (688131) closed at 62.68 yuan on August 25, 2025, with an increase of 6.51% and a turnover rate of 4.28% [1] - The company reported a total revenue of 606 million yuan for Q1 2025, representing a year-on-year growth of 20.05%, and a net profit attributable to shareholders of 62.38 million yuan, up 272.28% year-on-year [1] - The company has a current ratio of 2.466, a quick ratio of 1.560, and a debt-to-asset ratio of 47.96% [1] Group 2 - Haoyuan Pharmaceutical has made investments in 14 companies and participated in 17 bidding projects [2] - The company holds 64 trademark registrations and 89 patent registrations, along with 119 administrative licenses [2]

Market Performance - On August 22, the medical services sector rose by 1.29%, with Berry Genomics leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Top Gainers in Medical Services - Berry Genomics (000710) closed at 15.79, up 10.03% with a trading volume of 749,900 shares and a turnover of 1.153 billion yuan [1] - Haochen Medical (002622) closed at 4.21, up 9.92% with a trading volume of 1.4424 million shares and a turnover of 585 million yuan [1] - Golden Domain Medical (603882) closed at 11, up 4.02% with a trading volume of 148,600 shares and a turnover of 461 million yuan [1] Top Losers in Medical Services - Boji Pharmaceutical (300404) closed at 11.37, down 5.09% with a trading volume of 490,800 shares and a turnover of 557 million yuan [2] - ST Shenghua (000504) closed at 9.79, down 3.83% with a trading volume of 85,800 shares and a turnover of 84.73 million yuan [2] - Chengda Pharmaceutical (301201) closed at 30.34, down 3.38% with a trading volume of 104,000 shares and a turnover of 320 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 153 million yuan from institutional investors, while retail investors saw a net inflow of 246 million yuan [2][3] - Berry Genomics had a net inflow of 468 million yuan from institutional investors, but a net outflow of 214 million yuan from speculative funds [3] - Haochen Medical saw a net inflow of 116 million yuan from institutional investors, with a net outflow of 82.73 million yuan from speculative funds [3]

Group 1 - The restructuring protein concept declined by 0.85%, ranking among the top declines in the concept sector, with leading decliners including Beida Pharmaceutical, Saiseng Pharmaceutical, and Rejing Bio [1][2] - Among the 39 stocks in the restructuring protein sector, 18 stocks saw price increases, with Zhongyuan Qihua, Huaxi Bio, and *ST Wanfang leading the gains at 3.27%, 2.53%, and 2.23% respectively [1][2] - The restructuring protein sector experienced a net outflow of 789 million yuan from main funds today, with Shenzhou Cell seeing the largest outflow of 75.26 million yuan [2][3] Group 2 - The top gainers in the concept sector included Tonghuashun Fruit Index at 3.70%, AI Mobile at 2.77%, and National Big Fund Holdings at 2.76%, while the monkeypox concept declined by 0.86% [2] - The main funds saw net inflows in stocks such as Huaxi Bio, Guoyao Modern, and Haoyuan Pharmaceutical, with inflows of 47.54 million yuan, 21.85 million yuan, and 20.45 million yuan respectively [2][4] - The restructuring protein concept's outflow list included stocks like Shenzhou Cell, Ruizhi Pharmaceutical, and Kexing Pharmaceutical, with respective outflows of 75.26 million yuan, 70.92 million yuan, and 65.90 million yuan [2][3]

Market Overview - On August 20, the medical services sector rose by 0.33% compared to the previous trading day, with Haocen Medical leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Top Gainers in Medical Services - Haocen Medical (002622) closed at 3.96, up 10.00% with a trading volume of 827,000 shares and a transaction value of 322 million yuan [1] - Meinian Health (002044) closed at 5.87, up 4.45% with a trading volume of 2,284,200 shares and a transaction value of 1.323 billion yuan [1] - Baicheng Pharmaceutical (301096) closed at 56.47, up 3.31% with a trading volume of 72,900 shares and a transaction value of 401 million yuan [1] Top Losers in Medical Services - Innovation Medical (002173) closed at 23.05, down 7.21% with a trading volume of 1,255,900 shares and a transaction value of 2.968 billion yuan [2] - Boji Pharmaceutical (300404) closed at 12.36, down 6.01% with a trading volume of 819,000 shares and a transaction value of 1.015 billion yuan [2] - Nanmo Biological (688265) closed at 61.50, down 5.38% with a trading volume of 32,800 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 2.075 billion yuan from institutional investors, while retail investors saw a net inflow of 1.893 billion yuan [2][3] - The top net inflow from retail investors was in Meinian Health (002044) with 201 million yuan, despite a net outflow from institutional investors [3] - Haocen Medical (002622) had a net inflow of 114 million yuan from institutional investors, but also faced significant outflows from retail investors [3]

Core Insights - A total of 38 stocks on the Shanghai and Shenzhen exchanges have experienced net inflows of main funds for five consecutive days or more as of August 14, with Dingyang Technology leading at 10 days of inflow [1][2] - The stock with the highest total net inflow amount is Taicheng Light, which has seen a cumulative net inflow of 843 million yuan over six days [1] - The stock with the highest net inflow ratio relative to trading volume is Dayuan Pump Industry, which has increased by 48.78% over the past five days [1] Summary by Category Stocks with Continuous Net Inflows - Dingyang Technology: 10 days of net inflow, 73 million yuan, 6.82% increase [2] - Chinese Media: 9 days of net inflow, 83 million yuan, 1.20% increase [1][2] - Taicheng Light: 6 days of net inflow, 843 million yuan, 15.94% increase [1] Highest Net Inflow Amounts - Taicheng Light: 843 million yuan over 6 days [1] - Huicheng Environmental Protection: 746 million yuan over 9 days [1] - Huatai Securities: 666 million yuan over 5 days [1] Highest Net Inflow Ratios - Dayuan Pump Industry: 14.72% net inflow ratio, 48.78% increase over 5 days [1] - Huicheng Environmental Protection: 10.16% net inflow ratio, 26.41% increase over 9 days [1] - Huatai Securities: 5.24% net inflow ratio, 7.80% increase over 5 days [1]

每经AI快讯，有投资者在投资者互动平台提问：公司号称服务了adc企业中的95%的企业，请问是公司 adc项目覆盖了具备adc项目的企业的95%吗？毕竟公司还有一大堆试剂每年服务对象几万家，另外一个 企业又有非常多的管线项目，总不能把试剂服务的企业或者非adc项目也统计到adc企业中的95%？ （记者 王晓波） 皓元医药（688131.SH）8月13日在投资者互动平台表示，据不完全统计，2024年至今，XDC出海交易 金额高达280亿美元，交易数量达到27笔之多。其中，22家ADC出海的国内公司中，皓元医药服务了超 过95%的此类客户，合作形式包括ADC小分子部分的技术服务与中间体产品供应。 凭借在ADC领域多 年的深耕和积累，公司在ADC业务小分子领域形成了较强竞争优势。2024年，公司承接的ADC项目数 超过了110个，活跃客户近千家，截至2025年3月底，公司申请ADC相关的国内发明专利12项，国际发 明专利2项，完成了13个与ADC药物相关的小分子产品美国FDA DMF的备案。 ...

Core Viewpoint - The company, Haoyuan Pharmaceutical, is actively engaged in the innovative drug sector, providing essential services for clinical trial applications and drug production, with a significant number of projects underway across various global markets [1] Group 1: Business Model and Services - The company's innovative drug-related business model includes quality research and sample preparation services for clinical trial applications [1] - It also offers production services for active pharmaceutical ingredients (APIs) or intermediates in preclinical and clinical stages, as well as commercial production of intermediates for patented drugs [1] Group 2: Project Portfolio and Market Presence - As of the end of 2024, the company has undertaken a total of 892 projects, primarily focused on markets in China, Japan, South Korea, the United States, and Europe [1] - The majority of these projects are in the preclinical and Phase I clinical stages, with some products advancing to Phase II, Phase III, or new drug application stages [1] - The ongoing research projects are expected to enhance the global innovative drug development industry [1]

天眼查商业履历信息显示，上海皓元医药股份有限公司，成立于2006年，位于上海市，是一家以从事科 技推广和应用服务业为主的企业。企业注册资本21095.9781万人民币，实缴资本743.5514万人民币。公 司法定代表人为郑保富。 通过天眼查大数据分析，上海皓元医药股份有限公司共对外投资了14家企业，参与招投标项目17次，知 识产权方面有商标信息64条，专利信息89条，此外企业还拥有行政许可118个。 金融界消息 截至2025年8月13日收盘，皓元医药（688131）报收于54.88元，上涨3.82%，换手率 3.55%，成交量7.53万手，成交金额4.11亿元。 资金流向方面，今日主力资金净流入3813.19万元，占比成交额9.28%。其中，超大单净流入1149.94万 元、占成交额2.8%，大单净流入2663.25万元、占成交额6.48%，中单净流出流入300.64万元、占成交额 0.73%，小单净流出4113.84万元、占成交额10.02%。 皓元医药最新一期业绩显示，截至2025一季报，公司营业总收入6.06亿元、同比增长20.05%，归属净利 润6238.44万元，同比增长272.28%，扣非净利润5 ...